AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2403486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice containing 1,000 ppm fluoride with 1% disodium azacycloheptylidene-2.2-bisphosphonate (AHBP)
Number of subjects: 1161
Study 2403486 — intervention group
Group type: COMPARATOR
Intervention: Positive control: Monofluorophosphate dentifrice (1,000 ppm fluoride)
Number of subjects: 1161
Study 347884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol (1 mg tablets, initial dose: 1 mg, mean dose at end: 4.47 mg)
Number of subjects: 60
Study 347884 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (as reference substance)
Number of subjects: 60
Study 347884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 60
Study 347884 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 60
Study 31735487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehacop group (RG)
Number of subjects: 124
Study 29331031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder body injection of 100U BoNT‐A in 10 mL saline
Number of subjects: 39
Study 29331031 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigonal injection of 100U BoNT‐A in 10 mL saline
Number of subjects: 39
Study 28928048 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (15mg in 5 patients, 30mg in 23 patients)
Number of subjects: 60
Study 28928048 — intervention group
Group type: COMPARATOR
Intervention: Non-edoxaban group
Number of subjects: 60
Study 28928048 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 60
Study 26193635 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause)
Number of subjects: 49
Study 23771104 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 100 mg
Number of subjects: 32
Study 23771104 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 200 mg
Number of subjects: 32
Study 23771104 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 300 mg
Number of subjects: 32
Study 23771104 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986001 600 mg
Number of subjects: 32
Study 23771104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20188783 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer Tri‐Cure Glass Ionomer System
Number of subjects: 48
Study 20188783 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom
Number of subjects: 48
Study 20188783 — intervention group
Group type: EXPERIMENTAL
Intervention: TPH Spectrum
Number of subjects: 48
Study 20188783 — intervention group
Group type: COMPARATOR
Intervention: Class II cavity preparation
Number of subjects: 48
Study 19018047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 0
Study 19018047 — intervention group
Group type: COMPARATOR
Intervention: Currently recommended follow‐up procedures
Number of subjects: 0
Study 17690522 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing rubber gloves in addition to local ventilation
Number of subjects: 42
Study 17690522 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (workers from other departments)
Number of subjects: 42
Study 13679938 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant granulocyte colony-stimulating factor (rG-CSF)
Number of subjects: 10
Study 13679938 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 10752802 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional therapy with colloid and dobutamine (5 microg/kg/min then 10 microg/kg/min) for patients with pHi <7.35
Number of subjects: 210
Study 10752802 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard resuscitation without additional therapy)
Number of subjects: 210
Study 10752802 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional therapy with colloid and dobutamine for patients with gastric mucosal pH of > or =7.35 at admission
Number of subjects: 210
Study 10752802 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard resuscitation without additional therapy) for patients with gastric mucosal pH of > or =7.35 at admission
Number of subjects: 210
Study 8694326 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil infusion at lumbar level (1 microgram/mL)
Number of subjects: 37
Study 8694326 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil infusion at thoracic level (1 microgram/mL)
Number of subjects: 37
Study 8694326 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil combined with bupivacaine at thoracic level (1 mg/mL)
Number of subjects: 37
Study 1442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 24
Study 1442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 24
Study 1442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 24
Study 1442581 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 24
Study 1442581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6374885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (20 ml Aethoxysclerol 1%)
Number of subjects: 126
Study 6374885 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 126
Study 31872435 — intervention group
Group type: EXPERIMENTAL
Intervention: Power analysis method for CRTs with K≥2 binary co‐primary endpoints
Number of subjects: 0
Study 29429607 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized 'activity fingerprint' message
Number of subjects: 79
Study 29429607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity fingerprint)
Number of subjects: 79
Study 27707509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fursultiamine
Number of subjects: 24
Study 27707509 — intervention group
Group type: COMPARATOR
Intervention: Benfotiamine
Number of subjects: 24
Study 27707509 — intervention group
Group type: COMPARATOR
Intervention: Thiamine nitrate
Number of subjects: 24
Study 24800998 — intervention group
Group type: EXPERIMENTAL
Intervention: FE 999049 (recombinant follicle-stimulating hormone from human cell line)
Number of subjects: 0
Study 22244399 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 98
Study 22244399 — intervention group
Group type: COMPARATOR
Intervention: Open pyloromyotomy
Number of subjects: 98
Study 20087375 — intervention group
Group type: COMPARATOR
Intervention: Salba (0, 7, 15 or 24 g baked into white bread)
Number of subjects: 11
Study 17229792 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive chlamydia screening using mailed home‐collected specimens
Number of subjects: 0
Study 17229792 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive chlamydia screening
Number of subjects: 0
Study 16141740 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (70 units total, 40 units in the medial aspect of the heel, 30 units in the arch of the foot)
Number of subjects: 27
Study 16141740 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 27
Study 11799500 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA + IVN
Number of subjects: 47
Study 11799500 — intervention group
Group type: EXPERIMENTAL
Intervention: IVN
Number of subjects: 47
Study 11799500 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA
Number of subjects: 47
Study 11799500 — intervention group
Group type: COMPARATOR
Intervention: PCA + IVN
Number of subjects: 47
Study 10624956 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing three-dimensional displays
Number of subjects: 0
Study 10624956 — intervention group
Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 0
Study 7856520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (48-hour treatment)
Number of subjects: 194
Study 7856520 — intervention group
Group type: COMPARATOR
Intervention: Isotonic glucose (placebo)
Number of subjects: 194
Study 1835251 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (Seroxat, Aropax)
Number of subjects: 36
Study 1835251 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 36
Study 6801959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 11
Study 6801959 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 11
Study 30231262 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching a standardized videoclip during sleep induction with propofol
Number of subjects: 50
Study 30231262 — intervention group
Group type: COMPARATOR
Intervention: Not watching a standardized videoclip during sleep induction with propofol
Number of subjects: 50
Study 28975821 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting blood cardioplegia (adenosine 12 mg via aortic root, followed by a single dose of long-acting solution at 14℃, 30 mL/kg)
Number of subjects: 100
Study 28975821 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas' cardioplegia (initial 30 mL/kg at 14℃, followed by 15 mL/kg every 20 min)
Number of subjects: 100
Study 25355310 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-825
Number of subjects: 230
Study 25355310 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 230
Study 24457490 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B Hemoperfusion
Number of subjects: 0
Study 24457490 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21955930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (experimental group)
Number of subjects: 3000
Study 21955930 — intervention group
Group type: COMPARATOR
Intervention: No nicotine patches (control group)
Number of subjects: 3000
Study 19401574 — intervention group
Group type: EXPERIMENTAL
Intervention: First-pass imaging
Number of subjects: 84
Study 19401574 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state imaging
Number of subjects: 84
Study 19401574 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined imaging (first-pass plus steady-state)
Number of subjects: 84
Study 17341511 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent feedback
Number of subjects: 36
Study 17341511 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal feedback
Number of subjects: 36
Study 17341511 — intervention group
Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 36
Study 15080061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprostatic injection of Chuanshentong (6 ml mixed with lidocaine, once a day for 6 days)
Number of subjects: 38
Study 15080061 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection containing lidocaine
Number of subjects: 38
Study 15080061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 11448705 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management and relaxation with guided imagery
Number of subjects: 45
Study 11448705 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 45
Study 9669244 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis
Number of subjects: 362
Study 9669244 — intervention group
Group type: COMPARATOR
Intervention: Hospital thrombolysis
Number of subjects: 362
Study 9669244 — intervention group
Group type: COMPARATOR
Intervention: Single ECG
Number of subjects: 362
Study 9669244 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial ECGs
Number of subjects: 362
Study 7932682 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback with differing instructions
Number of subjects: 40
Study 7932682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 2842137 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1.0 mg i.v.)
Number of subjects: 0
Study 2842137 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia with midazolam and alfentanil
Number of subjects: 0
Study 29148893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity delayed intensification (protocol III; P-III)
Number of subjects: 1164
Study 29148893 — intervention group
Group type: COMPARATOR
Intervention: Standard delayed intensification (protocol II; P-II)
Number of subjects: 1164
Study 28025434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic stroke patients
Number of subjects: 86
Study 28025434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no previous stroke)
Number of subjects: 86
Study 25635970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral, rectal or vaginal misoprostol
Number of subjects: 248
Study 25635970 — intervention group
Group type: COMPARATOR
Intervention: No-treatment option
Number of subjects: 248
Study 23089080 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional air-purifying respirator (APR)
Number of subjects: 16
Study 23089080 — intervention group
Group type: EXPERIMENTAL
Intervention: Loose-fitting powered air-purifying respirator-hood (PAPR-hood)
Number of subjects: 16
Study 23089080 — intervention group
Group type: COMPARATOR
Intervention: Control (unprotected)
Number of subjects: 16
Study 20567999 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP-PTH 20 µg
Number of subjects: 0
Study 20567999 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP-PTH 30 µg
Number of subjects: 0
Study 20567999 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP-PTH 40 µg
Number of subjects: 0
Study 20567999 — intervention group
Group type: COMPARATOR
Intervention: FORTEO® injection
Number of subjects: 0
Study 20567999 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 20567999 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP-PTH
Number of subjects: 0
Study 19018250 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (standard open discectomy)
Number of subjects: 1244
Study 19018250 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 1244
Study 16569219 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS 2.5 g/d
Number of subjects: 200
Study 16569219 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS 5 g/d
Number of subjects: 200
Study 16569219 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS 7.5 g/d
Number of subjects: 200
Study 16569219 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS 10 g/d
Number of subjects: 200
Study 16569219 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS (all doses)
Number of subjects: 200
Study 16569219 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS 2.5 g/d and 5 g/d
Number of subjects: 200
Study 12691651 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark System TiUnite surface implants
Number of subjects: 44
Study 12691651 — intervention group
Group type: COMPARATOR
Intervention: Brånemark System machined-surface implants
Number of subjects: 44
Study 11890519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phentolamine (Vasomax) 40 mg before sleep
Number of subjects: 5
Study 11890519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) at 30 L x min(‐1)
Number of subjects: 13
Study 9623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) at 60 L x min(‐1)
Number of subjects: 13
Study 9623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) at 90 L x min(‐1)
Number of subjects: 13
Study 9623694 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) changes from 30 to 90 L x min(‐1)
Number of subjects: 13
Study 9623694 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LTP and QP groups
Number of subjects: 13
Study 7841626 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 0
Study 7841626 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants with LCP-enriched formula
Number of subjects: 0
Study 7841626 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants with commercially available formula without LCPs
Number of subjects: 0
Study 2905588 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil combined with low concentrations of isoflurane (group 1)
Number of subjects: 3
Study 2905588 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil combined with higher concentrations of isoflurane (group 2)
Number of subjects: 3
Study 2905588 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane without opioids (group 3)
Number of subjects: 3
Study 31880055 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (CP)
Number of subjects: 50
Study 31657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Given-NIC (given nicotine)
Number of subjects: 40
Study 31657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Told-NIC (told-nicotine)
Number of subjects: 40
Study 31657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette-related pictures
Number of subjects: 40
Study 31657594 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent trials (smoking or unpleasant)
Number of subjects: 40
Study 27757553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Number of subjects: 186
Study 27757553 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 1.25 mg
Number of subjects: 186
Study 25500485 — intervention group
Group type: EXPERIMENTAL
Intervention: New twice daily sustained-release (SR) paracetamol formulation (2 x 1,000 mg)
Number of subjects: 28
Study 25500485 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) paracetamol (2 x 500 mg)
Number of subjects: 28
Study 25500485 — intervention group
Group type: COMPARATOR
Intervention: Extended-release (ER) paracetamol (2 x 665 mg)
Number of subjects: 28
Study 23650792 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with cervical plexus block (EA+CPB)
Number of subjects: 40
Study 23650792 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture plus cervical plexus block (sham group)
Number of subjects: 40
Study 21481542 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic-enhanced information
Number of subjects: 102
Study 21481542 — intervention group
Group type: COMPARATOR
Intervention: Text-only information
Number of subjects: 102
Study 19904268 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐5‐FU arm (5-fluorouracil 350 mg m(‐2) per day during radiotherapy)
Number of subjects: 95
Study 19904268 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐GC arm (gemcitabine 300 mg m(‐2) and cisplatin 30 mg m(‐2) on days 1, 8, 22, and 29)
Number of subjects: 95
Study 19904268 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐GC+GC arm (same concurrent treatment followed by sequential full-dose gemcitabine 1000 mg m(‐2) and cisplatin 50 mg m(‐2) every 2 weeks)
Number of subjects: 95
Study 17013570 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance program
Number of subjects: 0
Study 17013570 — intervention group
Group type: COMPARATOR
Intervention: Dummy run procedure
Number of subjects: 0
Study 15310642 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine PCA plus a background infusion (group PCA-B)
Number of subjects: 60
Study 15310642 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA alone (group PCA-A)
Number of subjects: 60
Study 11123499 — intervention group
Group type: EXPERIMENTAL
Intervention: Paeoniae Radix (1.2 g extract powder once daily for 7 days) + 200 mg VPA on day 7
Number of subjects: 6
Study 11123499 — intervention group
Group type: COMPARATOR
Intervention: 200 mg VPA gastro-resistant tablet alone on day 7
Number of subjects: 6
Study 9569797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 25
Study 9569797 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 25
Study 8436990 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous impulse system (pumped group)
Number of subjects: 74
Study 8436990 — intervention group
Group type: COMPARATOR
Intervention: Standard thrombosis prophylaxis (nonpumped group)
Number of subjects: 74
Study 31738372 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 400 mg/d
Number of subjects: 554
Study 31738372 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/d
Number of subjects: 554
Study 31738372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 31738372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Minocycline (400 mg/d and 200 mg/d)
Number of subjects: 554
Study 31738372 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 400 mg/d vs 200 mg/d
Number of subjects: 554
Study 31454264 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine (1.5% arginine, fluoride-free)
Number of subjects: 83
Study 31454264 — intervention group
Group type: COMPARATOR
Intervention: Fluoride (1,100 ppm F/NaF)
Number of subjects: 83
Study 29157230 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 0
Study 26700994 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiwanese mother‐friendly childbirth model (experimental group)
Number of subjects: 751
Study 26700994 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (control group)
Number of subjects: 751
Study 24024532 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study 24024532 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine or Citalopram
Number of subjects: 0
Study 24024532 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine or Venlafaxine
Number of subjects: 0
Study 21288346 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention providing an information module and an e-coach module.
Number of subjects: 170
Study 21288346 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to a website with hyperlinks to commonly available information only.
Number of subjects: 170
Study 21288346 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 170
Study 21288346 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study 18256066 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 9
Study 18256066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9